# A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT07744126** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 150 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Telisotuzumab Adizutecan
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Fluorouracil

## Key facts

- **NCT ID:** NCT07744126
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744126, "A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07744126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*